TP53 and colon carcinoma: The HCT116 human colon carcinoma line, generously provided by Dr. B. Vogelstein, was chosen for study because it was available in two forms, one of which lacked the p53 pathway; this enabled assessment of the role of the p53 pathway in cellular responses to this drug [28].